Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Transcriptomic profiling of CASSIOPEIA pts identified 5 subtypes and 3 risk categories w/ 72-month PFS rates of 70%/51%/27% and refined value of MRD by identifying high-risk pts in whom MRD was insufficient to predict outcome.”
Title: Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma
Authors: Florence Magrangeas, Catherine Guérin-Charbonnel, Victor Bessonneau-Gaborit, Marie Denoulet, Nils Giordano, Aurore Perrot, Cyrille Touzeau, Mark van Duin, Magali Devic, Elise Douillard, Eric Letouzé, Pieter Sonneveld, Jill Corre, Stéphane Minvielle, Philippe Moreau
You can read the Full Article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
